The National Heart, Lung, and Blood Institute (NHLBI) awarded Ogb5, Inc. a $320,251 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to develop a non-viral nanoparticle gene therapy delivery platform for treating cystic fibrosis and other chronic lung diseases. The project aims to demonstrate that Ogb5's proprietary DNA and RNA nanoparticle technology can effectively deliver therapeutic amounts of the cystic fibrosis transmembrane conductance regulator (CFTR) gene in cell culture, animal models, and human subjects. The project will further refine the nanoparticle system, explore different delivery formulations, and establish the efficacy of this revolutionary gene therapy approach in a commercially available product. The grant period runs from July 1, 2024 to June 30, 2025.
Generated 3/4/25, 7:03 AM